Reckon you can show me evidence of where "the FDA concentrates on other technologies and keeps them waiting and sending them home to submit another application over and over again"
Delay in IND submission is due to issues around scaling up the manufacturing process, which is required for IND submission. non-clinical IND-enabling studies are still being completed.
Also, as ive metioned to you previously before, iNKT is not your standard T-Cell therapy. Its a completely different set of immune cells. As are CHMs NK cells.
You might want to brush up on your science before spruiking these things as "facts"
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)